Intellia Therapeutics (NTLA) Receivables (2015 - 2026)

Intellia Therapeutics (NTLA) has reported Receivables for 12 consecutive years, with $9.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Receivables fell 13.07% year-over-year to $9.1 million; the TTM figure through Mar 2026 stood at $9.1 million (down 13.07% YoY), while the FY2025 annual figure was $9.5 million, up 11.54% from the prior year.
• Receivables slipped to $9.1 million in Q1 2026 per NTLA's latest filing, from $9.5 million in the prior quarter.
• Across five years, Receivables topped out at $37.5 million in Q4 2023 and bottomed at $3.6 million in Q1 2022.
• Historically, Receivables has averaged $11.6 million across 5 years, with a median of $8.9 million in 2024.
• Annual changes were most pronounced in 2023 — Receivables jumped 597.76% — and 2024, when it tumbled 77.26%.
• Intellia Therapeutics' Receivables stood at $5.4 million in 2022, then surged by 597.76% to $37.5 million in 2023, then sank by 77.26% to $8.5 million in 2024, then gained by 11.54% to $9.5 million in 2025, then retreated by 3.88% to $9.1 million in 2026.
• Business Quant data shows NTLA's Receivables at $9.1 million in Q1 2026, $9.5 million in Q4 2025, and $11.0 million in Q3 2025.